ResultsIQ

ResultsIQ › Latest results › Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited Q1 FY26 results deck summary

NSE: SUNPHARMA · BSE: 524715

Results deck of 1 Sep 2025, summarised by AI from the filing.

Sun Pharma Q1 FY26 gross sales ₹137,861 mn (+10.1%), EBITDA ₹43,017 mn (+19.2%), net profit ₹22,786 mn (-19.6%); FY26 topline growth guided at mid to high single digit.

Key takeaways

  1. Q1 FY26 result Gross sales ₹137,861 mn (Q1 FY25: ₹125,245 mn, +10.1%); EBITDA ₹43,017 mn (+19.2%); net profit ₹22,786 mn (-19.6%).
  2. FY26 guidance Management targets mid to high single digit consolidated topline growth for FY26.
  3. Risk Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially.

Original filing on BSE

Sun Pharmaceutical Industries Limited Q1 FY27 results

As filed: Revenue ₹15,300 cr (+10% year on year), EBITDA ₹4,418 cr (+3% year on year), PAT ₹2,901 cr (+27% year on year), EBITDA margin 28.9% (−219 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹14,612 cr (+13% year on year), EBITDA ₹3,954 cr (+6% year on year), PAT ₹2,710 cr (+26% year on year), EBITDA margin 27.1% (−161 bps). Score 41 of 100, In line with trend. Revenue and profit growth were above the company's own trend; EBITDA growth was well below it. EBITDA margin fell 161 bps year on year. Consolidated profit +26% but standalone -70%. Revenue fell 6% from last quarter. Share price after the results: −0.9% in 30 days (Nifty 500: +1.0%).
  • Q3 FY26: Revenue ₹15,521 cr (+14% year on year), EBITDA ₹4,948 cr (+23% year on year), PAT ₹3,381 cr (+24% year on year), EBITDA margin 31.9% (+257 bps). Score 66 of 100, Above trend. Revenue and profit before exceptional items growth were above the company's own trend; EBITDA growth was well above it. EBITDA margin rose 257 bps year on year. Consolidated profit +16% but standalone -40%. Profit before exceptional items rose ₹925 cr on a year ago, more than the ₹722 cr it added the year before. Share price after the results: +9.9% in 30 days (Nifty 500: −1.1%).
  • Q2 FY26: Revenue ₹14,478 cr (+9% year on year), EBITDA ₹4,528 cr (+15% year on year), PAT ₹3,125 cr (+3% year on year), EBITDA margin 31.3% (+164 bps). Score 41 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend; profit growth was below it. EBITDA margin rose 164 bps year on year. Consolidated profit +3% but standalone -35%. Share price after the results: +6.2% in 30 days (Nifty 500: +2.8%).
  • Q1 FY26: Revenue ₹13,851 cr (+9% year on year), EBITDA ₹4,303 cr (+19% year on year), PAT ₹2,293 cr (+17% year on year), EBITDA margin 31.1% (+255 bps). Score 52 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA growth was above it; profit before exceptional items growth was well below it. EBITDA margin rose 255 bps year on year. Consolidated profit -20% but standalone +217%. Profit lagged EBITDA because of depreciation, interest or other income, not the business. Share price after the results: −8.0% in 29 days (Nifty 500: −2.5%).
  • Q4 FY25: Revenue ₹12,959 cr (+8% year on year), EBITDA ₹3,716 cr (+22% year on year), PAT ₹2,154 cr (+24% year on year), EBITDA margin 28.7% (+334 bps). Score 60 of 100, In line with trend. Revenue and profit before exceptional items growth were in line with the company's own trend; EBITDA growth was well above it. EBITDA margin rose 334 bps year on year. Consolidated profit -19% but standalone +130%. Revenue fell 5% from last quarter. Profit before exceptional items rose ₹698 cr on a year ago, more than the ₹507 cr it added the year before. Share price after the results: −3.1% in 29 days (Nifty 500: +2.0%).
  • Q3 FY25: Revenue ₹13,675 cr (+10% year on year), EBITDA ₹4,009 cr (+15% year on year), PAT ₹2,913 cr (+14% year on year), EBITDA margin 29.3% (+123 bps). Score 54 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it; profit growth was well below it. EBITDA margin rose 123 bps year on year. Profit fell 4% from last quarter. Profit rose ₹352 cr on a year ago, against ₹380 cr the year before.
  • Q2 FY25: Revenue ₹13,291 cr (+9% year on year), EBITDA ₹3,939 cr (+24% year on year), PAT ₹3,037 cr (+27% year on year), EBITDA margin 29.6% (+356 bps). Score 60 of 100, In line with trend. EBITDA margin rose 356 bps year on year. Consolidated profit +27% but standalone -3%. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Sun Pharmaceutical Industries Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.